Name:	ttph_ContractReceivableForResearchAndDevelopment
Namespace Prefix:	ttph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contract term.

+ References

No definition available.

+ Details

Name:	ttph_ContractTerm
Namespace Prefix:	ttph_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential future payments for regulatory milestones.

+ References

No definition available.

+ Details

Name:	ttph_PotentialFuturePaymentsForRegulatoryMilestones
Namespace Prefix:	ttph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront and milestone payments.

+ References

No definition available.

+ Details

Name:	ttph_UpfrontAndMilestonePayments
Namespace Prefix:	ttph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_ContractsRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of receivables that are derived from government contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 310
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68054760&loc=d3e55295-109406

+ Details

Name:	us-gaap_GovernmentContractReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromGrantors
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=ttph_BardaContractMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=ttph_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=ttph_CubrcIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=ttph_NiaidContractMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=ttph_NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ttph_SubcontractMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ttph_SubawardMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Agreements and Contracts - Additional Information (Detail) - USD ($)	1 Months Ended					12 Months Ended
	Jan. 31, 2012	Sep. 30, 2011	Jul. 31, 2011	Apr. 30, 2010	Jan. 31, 2007	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Feb. 29, 2012	Nov. 30, 2011	Oct. 31, 2011
BARDA Contract [Member] \| Biomedical Advanced Research and Development Authority (BARDA) [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Awarded contract for development, contract period	5 years
Government contract for research and development, amount	$ 67,300,000
BARDA Contract [Member] \| CUBRC Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contract expiration date						May 10, 2018
BARDA Contract [Member] \| CUBRC Inc [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Committed funding for subcontracts									$ 41,600,000
NIAID Contract [Member] \| CUBRC Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Committed funding for subcontracts										$ 900,000
Contract expiration date						Dec. 31, 2018
NIAID Contract [Member] \| CUBRC Inc [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Committed funding for subcontracts											$ 15,100,000
NIAID Contract [Member] \| National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Division [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Awarded contract for development, contract period		5 years	5 years
NIAID Contract [Member] \| National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Division [Member] \| Subcontract with CUBRC [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Committed funding for subcontracts						$ 15,100,000
Contract expiration date						Dec. 31, 2018
Proceed from awarded contract for development						$ 10,400,000
Contracts Revenue						2,200,000	$ 800,000	$ 2,100,000
NIAID Contract [Member] \| National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Division [Member] \| Subaward Under the NIAID Grant [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Committed funding for subcontracts						$ 900,000
Contract expiration date						May 31, 2017
Proceed from awarded contract for development						$ 800,000
Contracts Revenue						102,000	157,000	135,000
NIAID Contract [Member] \| National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Division [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Government contract for research and development, amount		$ 35,800,000
Awarded contract for development, amount			$ 2,900,000
License Agreement Terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront and milestone payments						$ 4,400,000
Number of common stock to be issued						31,379
Upfront and milestone payments						$ 15,100,000
Payment for additional intellectual property				$ 25,000	$ 25,000
Additional Funding Agreement Terms [Member] \| BARDA Contract [Member] \| CUBRC Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contract expiration date						May 10, 2018
Contract maturity date						May 10, 2018
Proceed from awarded contract for development						$ 32,400,000
Contracts Revenue						2,900,000	$ 10,800,000	$ 6,900,000
Additional Funding Agreement Terms [Member] \| BARDA Contract [Member] \| CUBRC Inc [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Committed funding for subcontracts						$ 41,600,000